Implant Sciences Wins CATSA Order for 122 Explosives Trace Detectors

Order advances Implant Sciences' capture of the North American ETD/Aviation Security Market with units to be deployed across Canadian airports this fiscal year

19 Jan, 2016, 10:52 ET from Implant Sciences Corporation

WILMINGTON, Mass., Jan. 19, 2016 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) solutions for Department of Homeland Security (DHS) applications, today reported that the company has received a previously unannounced order from the Canadian Air Transport Security Authority (CATSA) for up to 122 of its industry-leading QS-B220 desktop explosives trace detectors. These systems are planned to be deployed during the first half of 2016 (i.e., during Implant Sciences' current fiscal year ending June 30) to a number of Canadian airports for passenger and baggage screening.

"Implant Sciences' next generation non-rad trace detection technology has revolutionized the ETD industry," stated Dr. Darryl Jones, Implant Sciences' Executive Vice President. "The only fully-certified non-rad ETD on the market, the QS-B220 has been selected and deployed over the past year by numerous high-profile customers around the world, including the U.S. TSA, major European airports across 11 different countries, and now CATSA. We are pleased with this widespread adoption of our ETD technology and look forward to continuing this trend as we drive forward as the innovators of the ETD market."

"Implant Sciences is pleased that CATSA has selected the QS-B220 to meet the needs of their airports," stated Todd Swearingen, General Manager, Americas for Implant Sciences. "We are committed to elevating passenger experience while improving the security of aviation screening processes, and we are excited to deploy our technology to Canadian airports soon."

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 70 countries worldwide. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the 2015 GSN Airport/Seaport/Border Security Award for "Best Security Checkpoint". For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Cautionary Note Regarding Forward-Looking Statements

This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the "Company") related thereto contain or may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  Such statements are based on management's current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company's control) that could cause the Company's actual results to differ materially from the forward-looking statements.  Such risks and uncertainties include, but are not limited to (i) the risk that the deployment of the Company's devices in Canada as described here may not occur as planned, (ii) the risk that there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of the Company's explosives detection products or that any new products the Company may develop will be accepted by the TSA or by such other governments, agencies or consumers, (iii) economic, political and other risks associated with international sales and operations could adversely affect the Company's sales, (iv) the Company's business is subject to intense competition and rapid technological change, and the Company's ability to generate revenue and profit will depend on its ability to develop and introduce new products and (v) other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K.  In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements.  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Contact:

Implant Sciences Corporation
Company Contact:
Robert Liscouski
978-752-1700 x 116  

SOURCE Implant Sciences Corporation



RELATED LINKS

http://www.implantsciences.com